A Phase I Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRa;-Targeting Bispecific T-cell Engager, in Subjects with Relapsed/Refractory Ovarian Carcinoma
Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, Gyn/Onc (OB/GYNONC)
Current Status: Not open
Phase: I
Principal Investigator: Moore, Kathleen
Contact Information:
Marnee Strege
+1 402-559-8155
marnee.strege@unmc.edu
Summary
Primary:
-Evaluate the overall safety and tolerability of NTB-928
-Determine the optimal biologically active dose (OBD) of NTB-928
-Characterize the pharmacokinetic (PK) profile of NTB-928
-Characterize the immunogenicity profile of NTB-928
Secondary:
-Evaluate preliminary antitumor activity across various dose levels